PLENARY SYMPOSIUM IN THE ANNUAL MEETING OF THE ISEH

ISEH 年会全体研讨会

• 批准号: 3433987
• 负责人: KAREL A DICKE
• 金额: $ 1.5万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-04-01 至 1989-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3433987
• 关键词: bone marrow transplantation; hematopoietic growth factor; travel

The use of bone marrow transplantation as a therapeutic modality has expanded in recent years. No longer done in rare instances in only few institutions, bone marrow engraftment is done more frequently for rescue from high dose chemotherapy of solid tumors and leukemias, reconstitution in genetic immune deficiency and in a greater range of blood dyscrasias and aplasias throughout the world. More recently, the technique of marrow transplantation has been successfully applied to the correction of selected genetic enzyme deficiency diseases in laboratory animals and man, and is proposed as the strategy of choice for introducing altered or supplemental genetic information into higher organisms. We propose to use the 1988 meeting of the International Society for Experimental Hematology-- a society committed to the study of hematopoiesis and bone marrow transplantation--to organize a Plenary Symposium. The Plenary Symposium consists of eight sessions focused on bone marrow transplantation, hematopoietic growth factors and areas of molecular biology which open avenues for future therapeutic modalities in leukemia and other hematological disorders and for the understanding of the biology of leukemia and lymphoma. In addition to these, Session VII of Plenary Symposium is devoted to the Presidential Forum, a symposium on contemporary issues of experimental hematology. Such a Plenary Symposium exploits the gathering of intenationally-renowed basic and clinical scientists and offers a cost-effective mechanism for the exchange of laboratory and clinical results from around the world.

骨髓移植作为一种治疗方式的应用 近年来有所扩大。 在极少数情况下， 只有少数机构，骨髓移植做得更多 经常用于从高剂量化疗中抢救， 肿瘤和白血病，遗传免疫重建 缺乏和在更大范围的血液恶液质和aplasias 在全世界都有。 最近，骨髓移植技术 移植已成功地应用于矫正 实验动物的某些遗传酶缺乏病 和人，并提出作为战略的选择， 改变或补充遗传信息， 有机体 我们建议利用国际社会1988年的会议 实验血液学协会致力于研究 造血和骨髓移植--组织一个 全体座谈会。 研讨会由八个 骨髓移植、造血干细胞移植 生长因子和分子生物学领域开辟了道路 用于白血病和其他疾病的未来治疗方式 血液系统疾病和了解生物学 白血病和淋巴瘤 除此之外，第七届会议 全体专题讨论会专门讨论总统论坛， 实验血液学当代问题研讨会。 这样一个全体研讨会利用了聚集 有意知名的基础和临床科学家，并提供了一个 建立一个具有成本效益的机制， 来自世界各地的临床结果。